Low-grade serous carcinoma (LGSC) is a rare subtype of epithelial ovarian carcinoma with unique clinical characteristics and molecular features. Unlike high-grade serous carcinoma, LGSC typically occurs in younger women, follows an indolent course, and is associated with better long-term survival. It can develop de novo or arise from a precursor lesion known as a serous borderline tumor. Accurate pathological differentiation between LGSC and other histological subtypes of ovarian carcinoma is crucial for appropriate management. Several factors can impact the overall prognosis of LGSC. The age at diagnosis, current smoking status, elevated body mass index, mutational status, expression of hormonal receptors, and the Ki-67 proliferation index are all potential prognostic indicators. Surgical intervention plays a central role in the treatment of LGSC to achieve complete microscopic removal of the tumor in cases of metastatic disease. Despite its relative resistance to chemotherapy, adjuvant platinum-based chemotherapy is the current standard of care for LGSC. Hormonal maintenance therapy following adjuvant chemotherapy has demonstrated improved outcomes. In cases of disease recurrence, treatment options include secondary cytoreductive surgery, chemotherapy, hormonal therapy, targeted therapy, and participation in clinical trials. The evolving field of genomic studies and targeted therapies hold promise for transforming the treatment landscape of LGSC. Continued research and advancements in these areas are expected to significantly improve outcomes for patients with LGSC.